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Clinical Evaluation of CHLORPROMAZINE HYDROCHLORIDE**
in Acute Nausea and Vomiting
L. A. SWINEHART, M . D.'*

The following report on the study of Chlorpromazine Hydrochloride was an
unbiased effort to gain knowledge of its applicability and success in treating the foflowing conditions: pcst-operative nausea and vomiting, hyperemesis gravidarum, and
nausea, vomiting and intractable pain in terminal carcinomatosis.
Chlorpromazine Hydrochloride was termed S. K. F.—2601-A in earlier reports,
and chemically is 10-(3-dimethyl-aminoprophyl)-2 Chlorphinothiazine Hydrochloride.
It was originaUy synthesized by the Rhone-Poulenc Research Laboratories in France,
and is known as "largactil" in Canada, England, France and Italy; as "Megaphin" in
Germany; as 'Ampliactil" in Argentia; as 'Amplictfl" in Brazil and "Hibirnal" in
Sweden.
MATERIAL.
Twenty-four patients were picked at random, and various doses were given according to the severity of the symptoms. A f l four cases of malignancy were suffering from
adenocarcinoma of the ovaries with generalized metastasis. The patients were subjected to the following gynecological procedures: vaginal hysterectomy with cystocelerectocele repair, eight patients; dilatation and curettage of uterus, six patients; bartholin
cyst removal, one patient; acute mesenteric adenitis, one patient. A f l cases, except the
mesenteric adenitis and hyperemesis, were acute with severe nausea and vomiting
following operations under general anesthesia. Almost 100 per cent of the patients
received ether as the general anesthetic though induced with sodium Seconal intravenously. All of them received morphine sulfate gr. 1/6 and scopolamine gr. 1/150
I . M . preoperatively with the usual preoperative nothing by mouth from midnight. A l l
patients were to receive regular diet as tolerated post-operatively. The hyperemesis
and mesenteric adenitis patients were on nothing by mouth, and thus received intravenous
supportive therapy.
RESULTS.
The results are best explained by comparative charting, and are, shown in Table 1.
The side effects were noted, with desired effects as well, and the dosage used.
Table 2 summarizes the per cent of good results of nausea and vomiting controlled
in relation to the side effects.
The commonest side effect was drowsiness which occurred in approximately 20
per cent. Other side effects were dry mouth—10 per cent faintness, tachycardia,
pyrosis, conjunctivitis and hypotension of approximately one to two per cent. There
was no jaundice noted in any patient.
DISCUSSION.
"Thorazine" is related chemically to antihistamine in that it is a Phenothiazine
derivative. However, its antihistaminic, antispasmodic and adrenolytic effects are of
such a low order that it accounts for practically none of the actions of the drug. It
is a central nervous system and autonomic depressent by modifying or interfering with
synaptic transfer of excessive psychomotor excitement between cortical areas and the
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diencephalon so that conscious perceptions are altered. It also acts to a lesser extent on ganglia and the peripheral autonomic system. It definitely potentiates, in-
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2.

Side Effects

Pt. No.

Diagnosis

Initial Dosage

Results

25mgm. I M a. c.
stopped vomiting
drowsiness faintness
25mgm. I M a. c. h. s.
poor results
drowsiness faintness
none
reduced demoral to 1/3 25mgm. I M a. c. h. s.
25mgm. I M a. c. h. s.
no change
none
25mgm. I M a. c. h. s.
good
none
fair
25mgm. 1 M a. c. h. s.
none
acute pyrosis
poor
25mgm. I M a. c. h. s.
25mgm. I M a. c. h. s.
good
none
25mgm. I M B. d.
good
none
25mgm. I M a. c. h. s.
good
none
25mgm. I M b. d.
good
none
25mgm. I M b. d.
good
none
25mgm. I M a.c.
good
none
25mgm. I M q. 6h.
good
none
No medicine
fair
none
25mgm. I M a. c.
good
acute drowsiness
25mgm. I M b. d.
good
none
25mgm. I M q. 6h.
good
none
25mgm. I M q. 6h.
poor
none
25mgm. orally q. 6h.
good
none
25mgm. I M a.c.
poor
acute drow.siness
25mgm. I M b. d.
fair
none
25mgm. I M a. c. h. s.
poor
none
conjunctivitis, acute
drowsiness

no benefit

25mgm. I M a. c. h. s.
varied c no benefit

D i a g n o s i s , side e f f e c t s results a n d dosag e.

Disease
Terminal carcinomatosis
Vaginal hysterectomy, cystocele-rectocele rep air
Dilatation and curettage
Hypertension
Hyperemesis gravidarum
Bartholin cyst excision
Mesenteric adenitis
Post radiation reaction

% Good Response

% Side Reactions

50%
88%
100%
100%
100%
0-poor
very poor
100%

50%
12%
12%
0%
50%
0%
100%
0%

p e r c e n t o f side effects in relation to the percent of
good, fair or poor response.

d i a g r a m illustrates the

tensifies and prolongs the action of various drugs—notably narcotics,^.^ hypnotics,
sedatives,* anesthetics,*''' alcohol and muscle relaxants. The important anti-emetic
effect is believed to result from blocking emetic impulses at the chemoreceptor trigger
zones and reticular mechanism in the medulla. It is a relatively non-toxic drug with no
clinical evidence to date of any damage to tissues, organs and body fluids from prolonged use, as wefl as free from addiction production.
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Its apparent site of detoxification is the liver and shows little effect on renal
function with only slightly increased sodium excretion observed. Friend and Cummins,^
showed it to be very effective against nausea and vomiting of uremia.
Its delightful effects were producing, as Howell, Harth and Dietrick,' described,
a curtain between the patient and his pain. Sadove, Levin, Rose, Schwartz and Witt,^
noted their patients spoke of their pain as an objective phenomenon.
It is essential to bear in mind that the dosage of "Thorazine" must be highly
individualized, varying widely from indication to indication; from patient to patient
and according to the severity of the condition and the degree of response in each
patient. Caution must be used and frequent blood pressure recordings must be ordered
on the charts of afl patients to detect early hypotention and possible shock, especially until tolerated maintenance dosages are established.
Although juandice occurs in very few cases, it has not been proven to date
that "Thorazine" is hepatotoxic, although the liver function tests are similar to those
in obstructive juandice, i . e. elevation of serum bilirubin, elevated alkaline phosphatase,
increased serum cholesterol concentration and detection of bile in the urine.
In the above cases oral administration was used when possible. However, almost
all were given initial doses I . M . to be followed by oral use as soon as tolerated. The
results, overall, were gratifying with the average percent of side effects in the same
range as those recorded by numerous other investigators.
SUMMARY
1. The many methods of administration of "Thorazine" makes it easily selectable to fit the individual.
2. The diversity of its pharmacologic action and the necessity of variation in
dosage emphasizes the importance of determining the optimal dosage regime for the
condition and for the individual.
3. The primary acute nausea and vomiting was well controlled in the majority
of patients in spite of the rather high incidence of side effects noted. However, most
patients preferred the side effects rather than the more distressing initial complaints.
4. Caution, and frequent blood pressure recordings, should be ordered on all
patients receiving "Thorazine" until the maintenance dose is ascertained.
5. The severity of the side effects of the drug varied according to the size dose
given, and many of these side effects are easily controlled by other drugs.
6. It is important to note that our evaluation was limited to a relatively small
number of patients. We found that for certain specific complaints, the drug produced
encouraging results. This may lead one to use the drug empiricafly to treat acute
nausea and vomiting which is certainly wrong, in that the cause of nausea and vomiting
should always be established before "Thorazine" is administered, so that the diagnosis
will not be obscured.
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